Business
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments.
In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall behind on those early drug trials.
These include hospital contracting as well as ethical reviews and approvals, both of which he called “clunky processes that take too long and are leaving us noncompetitive with the countries that are moving a lot faster.” He also pointed to the process for submitting and receiving approvals for Investigational New Drug, or IND, applications, which companies submit to test a product in humans.
“We walked into a mess,” Makary said, referring to how behind China the U.S. was in terms of Phase 1 clinical trials conducted in 2024.
Food and Drug Administration Commissioner Marty Makary speaks in the Oval Office at the White House on Jan. 29, 2026.
Samuel Corum | Getty Images
He said the FDA is “looking at everything,” such as whether it can partner with health systems and academic medical centers on the pre-IND process. That refers to when companies consult the FDA before formally filing an application.
Makary said the Trump administration should “partner with industry to help them deliver more cures and meaningful treatments for the American public because that is a common bipartisan goal that we all want. And we’re going to get it done in this administration.”
China’s biotech ecosystem has flourished over the last several years, driven by massive state investment, a vast talent pool and accelerated regulatory reforms. Once known for being a low-cost manufacturing base that pumps out copycats, China is rapidly evolving into a global innovation powerhouse.
Data from Global Data and Morgan Stanley shows that China now conducts more clinical trials than the U.S., accounts for nearly a third of new global drug approvals and is on pace to reach 35% of FDA approvals by 2040.
U.S. policymakers have been under pressure to take steps to boost innovation domestically.
Business
The two farms in Senegal that supply many of the UK’s vegetables
Between January and March, if you browse the fresh produce aisles of the UK’s biggest food retailers, including Tesco, Sainsbury’s, Asda, Aldi and Lidl, you’re likely to see spring onions, radishes, green beans, chillis, butternut squash, and cobs of corn, all labelled Produce of Senegal.
Business
PSX roars back with 5,700-point rally | The Express Tribune
Trade volumes fell to 175 million shares compared with Monday’s tally of 181 million. PHOTO: FILE
KARACHI:
The Pakistan Stock Exchange (PSX) delivered a powerful performance on Wednesday as it staged a strong comeback, driven by heavy buying in banking and fertiliser stocks amid strong corporate earnings.
The benchmark KSE-100 index surged 5,702.68 points, or 3.29%, and settled at 178,853.10. It touched the intra-day high of 178,974 and low of 174,329, reflecting heightened volatility.
The rally was primarily led by major banking and fertiliser stocks as investors responded positively to encouraging earnings announcements. Institutional participation and renewed investor confidence helped push the market sharply higher after recent hefty losses.
KTrade Securities wrote in its market wrap that the PSX staged a strong comeback as the KSE-100 index closed at 178,853, gaining 5,703 points. The rebound came after consecutive weak sessions, driven by settlement transition concerns, margin pressure and political noise. With some of those pressures easing, the market witnessed aggressive covering of positions and renewed buying interest, it said.
The recovery was broad-based, led by banks and fertiliser firms, while strong corporate earnings further supported sentiment. Notably, Habib Bank announced impressive results along with a dividend of Rs6 per share, boosting confidence across the banking space alongside other major names.
Overall sentiment has turned constructive after the sharp pullback. If stability continues and corporate results remain supportive, this rebound could sustain in the near term. However, sustainability will depend on liquidity flows and clarity on the broader political and macro environment, KTrade added.
Topline Securities noted that the KSE-100 index posted a gain of 5,703 points, reflecting recovery in the market. The index moved within a band, touching intra-day high of 178,974 and low of 174,329. Support from heavyweights such as United Bank, Habib Bank, Meezan Bank, National Bank and MCB Bank underpinned the market’s performance, adding 2,699 points. In contrast, Pakistan Oilfields, Pioneer Cement and Adamjee Insurance weighed on the index, trimming 163 points, it said.
JS Global analyst Muhammad Hasan Ather commented that the KSE-100 staged a massive recovery as the index surged 5,703 points. The bullish reversal erased nearly all losses from the prior four sessions.
The rally was triggered by the State Bank reporting a $121 million current account surplus for January and anticipation of a federal relief package for the construction sector. While banking and energy stocks led the charge, the outlook remains cautiously optimistic. Further gains hinge on sustained macroeconomic stability and the rollout of industrial policy support, Ather said.
Arif Habib Limited (AHL) reported that stocks experienced a solid bounce following a 10% drawdown with a 3.3% gain day-on-day. Some 91 shares rose while seven fell with United Bank (+7.41%), Habib Bank (+10%) and Meezan Bank (+5.9%) contributing the most to index gains. In contrast, Pioneer Cement (-9.51%), Pakistan Oilfields (-1.01%) and Adamjee Insurance (-2.81%) were the biggest index drags.
HBL announced CY25 earnings per share of Rs48.48, up 14% year-on-year, and dividend of Rs20. Earnings were in line and the payout – the highest-ever – was above expectations. The sharp rally brings 180k back into focus for the remaining week, AHL added.
Overall trading volumes decreased to 698 million shares compared with Tuesday’s tally of 716 million. The value of traded stocks stood at Rs50 billion.
Shares of 484 companies were traded. Of these, 334 stocks closed higher, 103 fell and 47 remained unchanged.
K-Electric continued to lead the volumes chart with trading in 117 million shares, rising Rs0.57 to close at Rs8.39. It was followed by The Bank of Punjab with 71.1 million shares, gaining Rs1.66 to close at Rs35.78 and Pakistan Petroleum with 27.6 million shares, higher by Rs1.92 to close at Rs236.86. Foreign investors sold shares worth Rs2.3 billion, the National Clearing Company reported.
Business
Seattle Seahawks begin sale process after Super Bowl win
Dareke Young #83 of the Seattle Seahawks celebrates with teammates during the third quarter of the NFC Championship game against the Los Angeles Rams at Lumen Field on Jan. 25, 2026 in Seattle, Washington.
Jane Gershovich | Getty Images
The Seattle Seahawks are officially up for sale.
The NFL team, which defeated the New England Patriots in the 2026 Super Bowl earlier this month, announced on Wednesday that it has begun a process through which it could sell the franchise. The process, led by investment bank Allen & Co. and law firm Latham & Watkins, is expected to continue through the 2026 offseason.
The Seahawks franchise is owned by the estate of Paul Allen, the Microsoft co-founder who helmed the Seahawks from 1997 until his death in 2018. His sister, Jody Allen, became executor of his estate after his death and took over the leadership of the franchise, overseeing the sale of his assets and donations to charity.
“The Estate of Paul G. Allen today announced it has commenced a formal sale process for the Seattle Seahawks NFL franchise, consistent with Allen’s directive to eventually sell his sports holdings and direct all Estate proceeds to philanthropy,” the franchise wrote on social media.
Prior to the Seahawks’ most recent Super Bowl win, the Seattle team was valued at roughly $7 billion, according to CNBC’s official NFL valuations. In that range, the sale has the potential to become one of the biggest in NFL history, after the Washington Commanders sold for roughly $6 billion in 2023.
A sale would be finalized after NFL owners ratify a purchase agreement, according to the Seahawks.
-
Business1 week agoAye Finance IPO Day 2: GMP Remains Zero; Apply Or Not? Check Price, GMP, Financials, Recommendations
-
Business1 week agoGold price today: How much 18K, 22K and 24K gold costs in Delhi, Mumbai & more – Check rates for your city – The Times of India
-
Fashion1 week agoComment: Tariffs, capacity and timing reshape sourcing decisions
-
Business6 days agoTop stocks to buy today: Stock recommendations for February 13, 2026 – check list – The Times of India
-
Fashion7 days agoIndia’s PDS Q3 revenue up 2% as margins remain under pressure
-
Politics7 days agoIndia clears proposal to buy French Rafale jets
-
Fashion1 week agoSaint Laurent retains top spot as hottest brand in Q4 2025 Lyst Index
-
Tech1 week agoRemoving barriers to tech careers
